Definium Therapeutics Inc

Research Definium Therapeutics Inc (DFTX) on Bullrun: market cap USD 5.08B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerDFTX
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 5.08B
• Financial periodFY2025
• Net income-USD 183.79M

Valuation Snapshot

latest market cap is USD 5.08B.

About Definium Therapeutics Inc

Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder.

Frequently asked questions

What is Definium Therapeutics Inc's market cap?

Definium Therapeutics Inc's market capitalization is USD 5.08B.

What does Definium Therapeutics Inc do?

Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders.